Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of tisagenlecleucel in elderly patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2019-002930-35Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Aug 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL), sponsored by University of Cologne. Primary endpoint: Complete metabolic response rate. Started Aug 2020; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2019-002930-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002930-35.